Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$115.52 USD
+0.89 (0.78%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $115.56 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Jazz Pharmaceuticals PLC has a PEG ratio of 0.58 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.85.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JAZZ 115.52 +0.89(0.78%)
Will JAZZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength?
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
Other News for JAZZ
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Aristotle Global Equity Q2 2025 Commentary
Jazz Pharmaceuticals (JAZZ) Price Target Adjusted by Morgan Stanley | JAZZ Stock News
Where Jazz Pharmaceuticals Stands With Analysts
Polaris International Equity Composite Q2 2025 Commentary